Ortho Development Receives FDA Clearance on Trivicta Hip System

Ortho Development Corporation, renowned for its orthopedic implants and instruments, has officially announced receiving FDA 510(k) clearance for its Trivicta™ Hip System on March 14, 2024. This clearance marks a significant achievement, affirming the system's compliance and safety for hip and knee joint replacement surgeries in the United States.

The Trivicta Hip System is distinguished by its triple-taper femoral stem, designed to accommodate a wide spectrum of patient anatomies, offering an optimal fit within the femoral canal. Brent Bartholomew, President & CEO of Ortho Development, asserted that Trivicta enhances the company's primary hip portfolio by integrating evolutionary innovation, emphasizing the system's flexibility to meet diverse patient and surgeon needs.

Trivicta's unique design features include a triple-tapered geometry for stability, two distinct coatings for both initial and long-term stability, and a process that preserves bone while ensuring an ideal fit. It also supports different surgical approaches, including muscle-sparing and traditional methods. Dr. Marc Hungerford highlighted the system's ability to adapt to various femoral morphologies, offering advantages in lateralization without affecting leg length.

Slated for a limited release in the second quarter of 2024 in the United States, Trivicta's full commercial launch is eagerly anticipated. This development promises to offer orthopedic surgeons an innovative option that accommodates a broader range of anatomical variances among patients undergoing hip replacement surgery.